SPC Life Science date has been confirmed from October, 2023 and ended on October, 2023.
The SPC Life Sciences IPO date is undisclosed; however, the IPO is expected to go public in October 2023 and close in October 2023. SPC Life Sciences IPO will generate approximately [.] crores through an IPO that includes a fresh issue of 300 crores and an offer for sale of up to 8,938,870 equity shares at a price of 10 rupees each. The retail quota is 35%, the QIB share is 50%, and the HNI share is 15%.
Start your investing journey today. How do you open your own demat account for free?
Bidding Dates
October, 2023
Price Range
Coming soon
Face Value
₹10 per Equity Share
GMP
Coming soon
SPC Life Sciences GMP
The SPC Life Sciences IPO GMP is ₹[ ].
IPO Overview
SPC Life Sciences IPO is scheduled to take place in October 2023, with the exact date yet to be determined. The IPO aims to raise approximately ₹[.] crores through a combination of a fresh issue of ₹300 crores and an offer for sale of up to 8,938,870 equity shares, each valued at ₹10. The allocation for retail investors is set at 35%, while qualified institutional buyers (QIB) will have a 50% allocation, and high net worth individuals (HNI) will have a 15% allocation.
SPC Life Sciences is a prominent Indian manufacturer specializing in the production of advanced intermediates for key active pharmaceutical ingredients (APIs). These APIs include Pentoxifylline, AmiodaroneHCL, Cilostazol, Trazodone, Tramadol, and Paroxetine. The company’s core focus lies in research and development (R&D) and chemical manufacturing, particularly in long-chain multi-stage reactions. Their range of advanced pharmaceutical intermediates (Pharma Intermediates) finds application in various therapeutic areas such as cardiovascular, vasodilator (anti-platelet), anti-psychotic, and anti-depressants. SPC Life Sciences holds a significant market share in India and globally for some of these products. Notably, they possess a US FDA-approved facility for 6-Chloro-Hexane-2-One, enabling them to develop Pharma Intermediates and collaborate with pharmaceutical companies seeking US FDA-compliant manufacturing facilities within their supply chain.
SPC Life Sciences IPO Date & Price Band Details
| IPO Open: | 2023 |
| IPO Close: | 2023 |
| IPO Size: | Approx ₹[.] Crores |
| Fresh Issue: | Approx ₹300 Crores |
| Offer for Sale: | Approx 8,938,870 Equity Shares |
| Face Value: | ₹10 Per Equity Share |
| IPO Price Band: | ₹[.] to ₹[.] Per Share |
| IPO Listing on: | BSE & NSE |
| Retail Quota: | 35% |
| QIB Quota: | 50% |
| NII Quota: | 15% |
| Discount: | N/A |
SPC Life Sciences IPO Market Lot
The minimum market lot for the SPC Life Sciences IPO is [.] shares, requiring an application amount of ₹[.]. Retail investors have the opportunity to apply for a maximum of 13 lots, which is equivalent to [.] shares or ₹[.] amount.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 1 | – | ₹- |
| Retail Maximum | 13 | – | ₹- |
| S-HNI Minimum | 14 | – | ₹- |
| B-HNI Minimum | 68 | – | ₹- |
SPC Life Sciences IPO Allotment and Listing Dates
The IPO date for SPC Life Sciences is scheduled for 2023, with the closing date set for October of the same year. The allotment for the SPC Life Sciences IPO will be completed in 2023, and the listing of the IPO is also expected to take place in the same year.
| Price Band Announcement: | 2023 |
| Anchor Investors Allotment: | 2023 |
| IPO Open Date: | 2023 |
| IPO Close Date: | 2023 |
| Basis of Allotment: | 2023 |
| Refunds: | 2023 |
| Credit to Demat Account: | 2023 |
| IPO Listing Date: | 2023 |
SPC Life Sciences Company Financial Report
| Year (₹ in Crores) | Revenue | Expense | PAT |
| 2020 | ₹121.10 | ₹106.92 | ₹10.38 |
| 2021 | ₹136.14 | ₹113.92 | ₹16.67 |
| 2022 | ₹146.44 | ₹120.56 | ₹19.23 |
SPC Life Sciences IPO Valuation – FY2022
Please review the valuation details of SPC Life Sciences IPO, including information on Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV).
| Earning Per Share (EPS): | ₹4.30 per Equity Share |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 28.00% |
| Net Asset Value (NAV): | ₹61.48 per Equity Share |
Company Profile
SPC Life Sciences is a significant manufacturer of advanced intermediates for essential active pharmaceutical ingredients (APIs) such as Pentoxifylline, AmiodaroneHCL, Cilostazol, Trazodone, Tramadol, and Paroxetine in India. They are a chemical manufacturing company that focuses on long-chain multi-stage reactions through research and development (R&D). They manufacture advanced pharmaceutical intermediates (Pharma Intermediates), which are used in a variety of growing therapeutic areas such as cardiovascular,
vasodilator (anti-platelet), anti-psychotics, and anti-depressants, with some of the products having a significant market share both in India and globally. They may produce Pharma Intermediates and work with pharmaceutical companies looking for US FDA-compliant manufacturing facilities as part of their supply chain because they have a US FDA-approved facility for 6-Chloro-Hexane-2-One.
Registrar Info
| Name | LINK INTIME INDIA PRIVATE LIMITED |
| Phone number | +91810 811 4949 |
| Email ID | spclifesciences.ipo@linkintime.co.in |
| Website | https://linkintime.co.in |
Contact Details
| Name | SPC Life Sciences |
| Phone number | +91 2652658894 |
| Email ID | cs@spcls.co.in |
| Website | https://www.spcls.co.in |
IPO Strenghts
- Experienced promoters and a competent management team.
- Well-established relationships with a loyal customer base.
- Access to markets worldwide, enabling global reach.
IPO Weakness
- Heavy reliance on customers based in the United States.
- Need to adhere to multiple laws and regulations in these countries to ensure compliance.
- Competition from other players in the market.
